Author

T. Shragai

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Ixazomib, pomalidomide and dexamethasone in triple-class exposed multiple myeloma patients - a phase II study.

Multi-class upfront regimens for multiple myeloma (MM) have improved outcomes, yet many patients become either triple-class exposed (TCE) or refractory (TCR) early in their disease course. This is a phase II, investigator initiated, open-label, single-arm, prospective, multicenter study evaluating all-oral Ixazomib-pom...

T. Shragai, N. Lavi, I. Vaxman et al. · Haematologica · 0 citations

Case report Open access Aug 2026

Bispecific Antibodies Are Associated With Progressive Multifocal Leukoencephalopathy

PML represents a rare but serious, life-threatening complication of BisAbs therapy in MM, and should be considered in patients receiving BisAbs therapy who develop new neurologic symptoms, and prompt evaluation is warranted.

Avi Gadoth, Y. Paran, Yair Mina et al. · Neurology(R) neuroimmunology... · 0 citations